Type 1 diabetes and osteoporosis: From molecular pathways to bone phenotype

Journal of Osteoporosis

Volumn 2015, Issue , 2015, Pages

  Khan, Tayyab S ^a   Fraser, Lisa Ann ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DICKKOPF 1 PROTEIN; OSTEOCALCIN; SCLEROSTIN; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2;

BONE DENSITY; BONE FRAGILITY; BONE MATRIX; BONE REMODELING; CELL ACTIVITY; CELL DIFFERENTIATION; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; FALL RISK; HIP FRACTURE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84927126850     PISSN: 20908059     EISSN: 20420064     Source Type: Journal    
DOI: 10.1155/2015/174186     Document Type: Review

References (84)

1. J. Y. Reginster and N. Burlet, "Osteoporosis: a still increasing prevalence, " Bone, vol. 38, no. 2, supplement 1, pp. S4-S9, 2006.
2. L. J. Melton III, E. A. Chrischilles, C. Cooper, A. W. Lane, and B. L. Riggs, "Perspective: howmanywomen have osteoporosis?" Journal of Bone andMineral Research, vol. 7, no. 9, pp. 1005-1010, 1992.
3. Y.-H. Hsu, X. Xu, H. A. Terwedow et al., "Large-scale genomewide linkage analysis for loci linked to BMDat different skeletal sites in extreme selected sibships, " Journal of Bone and Mineral Research, vol. 22, no. 2, pp. 184-194, 2007.
4. G. Yousefzadeh, B. Larijani, A. Mohammadirad et al., "Determination of oxidative stress status and concentration of TGF-β1 in the blood and saliva of osteoporotic subjects, " Annals of the New York Academy of Sciences, vol. 1091, pp. 142-150, 2006.
5. L. Warming, C. Hassager, and C. Christiansen, "Changes in bone mineral density with age in men and women: a longitudinal study, " Osteoporosis International, vol. 13, no. 2, pp. 105-112, 2002.
6. T. V. Nguyen, J. R. Center, and J. A. Eisman, "Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index, " Journal of Bone and Mineral Research, vol. 15, no. 2, pp. 322-331, 2000.
7. J. L. Kelsey, T. H. M. Keegan, M. M. Prill, C. P. Quesenberry Jr., and S. Sidney, "Risk factors for fracture of the shafts of the tibia and fibula in older individuals, " Osteoporosis International, vol. 17, no. 1, pp. 143-149, 2006.
8. P. W. Berney, "Osteoporosis and diabetes mellitus: report of a case, " Journal of the Iowa StateMedical Society, vol. 42, no. 1, pp. 10-12, 1952.
9. Centers for Disease Control and Prevention, National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2014, US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga, USA, 2014, http://www.cdc.gov/diabetes/pubs/pdf/ndfs2011.pdf.
10. P. Vestergaard, "Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetesandametaanalysis, " Osteoporosis International, vol. 18, no. 4, pp. 427-444, 2007.
11. M. Janghorbani, D. Feskanich, W. C. Willett, and F. Hu, "Prospective study of diabetes and risk of hip fracture: the nurses health study, " Diabetes Care, vol. 29, no. 7, pp. 1573-1578, 2006.
12. Scottish Diabetes Research Network Epidemiology Group, Life Expectancy in Type 1 Diabetes: A Scottish Registry Linkage Study, 2013, http://www.easdvirtualmeeting.org/resources/3906.
13. P. Gunczler, R. Lanes, V. Paz-Martinez et al., "Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally, " Journal of Pediatric Endocrinology and Metabolism, vol. 11, no. 3, pp. 413-419, 1998.
14. P. Gunczler, R. Lanes, M. Paoli, R. Martinis, O. Villaroel, and J. R. Weisinger, "Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type diabetes mellitus, " Journal of Pediatric Endocrinology and Metabolism, vol. 14, no. 5, pp. 525-528, 2001.
15. A. Stolzing, D. Sellers, O. Llewelyn, and A. Scutt, "Diabetes induced changes in rat mesenchymal stem cells, " Cells Tissues Organs, vol. 191, no. 6, pp. 453-465, 2010.
16. P. Jin, X. Zhang, Y. Wu et al., "Streptozotocin-induced diabetic rat-derived bone marrow mesenchymal stem cells have impaired abilities in proliferation, paracrine, antiapoptosis, and myogenic differentiation, " Transplantation Proceedings, vol. 42, no. 7, pp. 2745-2752, 2010.
17. A. Dienelt and N. I. Z. Nieden, "Hyperglycemia impairs skeletogenesis fromembryonic stem cells by affecting osteoblast and osteoclast differentiation, " Stem Cells and Development, vol. 20, no. 3, pp. 465-474, 2011.
18. H. Lu, D. Kraut, L. C. Gerstenfeld, and D. T. Graves, "Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation, " Endocrinology, vol. 144, no. 1, pp. 346-352, 2003.
19. H. Qi, D. J. Aguiar, S. M. Williams, A. la Pean, W. Pan, and C. M. Verfaillie, "Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 6, pp. 3305-3310, 2003.
20. A. Neve, A. Corrado, and F. P. Cantatore, "Osteocalcin: skeletal and extra-skeletal effects, " Journal of Cellular Physiology, vol. 228, no. 6, pp. 1149-1153, 2013.
21. K. Fulzele and T. L. Clemens, "Novel functions for insulin in bone, " Bone, vol. 50, no. 2, pp. 452-456, 2012.
22. M. Hie, N. Iitsuka, T. Otsuka, and I. Tsukamoto, "Insulindependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation, " International Journal of Molecular Medicine, vol. 28, no. 3, pp. 455-462, 2011.
23. L. F. Bonewald and M. L. Johnson, "Osteocytes, mechanosensing andWnt signaling, " Bone, vol. 42, no. 4, pp. 606-615, 2008.
24. M. E. Villarino, L. M. Sanchez, C. B. Bozal, and A. M. Ubios, "Influence of short-term diabetes on osteocytic lacunae of alveolar bone. A histomorphometric study., " Acta Odontologica Latinoamericana, vol. 19, no. 1, pp. 23-28, 2006.
25. S. Portal-Nunez, D. Lozano, L. Fernandez de Castro, A. R. de Gortazar, X. Nogues, and P. Esbrit, "Alterations of theWnt/betacatenin pathway and its target genes for the N-and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice, " FEBS Letters, vol. 584, no. 14, pp. 3095-3100, 2010.
26. L. Gennari, D. Merlotti, R. Valenti et al., "Circulating Sclerostin levels andbone turnover in type 1 and type2diabetes, " Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 5, pp. 1737-1744, 2012.
27. T. Neumann, L. C. Hofbauer, M. Rauner et al., "Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus, " Clinical Endocrinology, vol. 80, no. 5, pp. 649-655, 2014.
28. A. Catalano, B. Pintaudi, N. Morabito et al., "Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus, " European Journal of Endocrinology, vol. 171, no. 3, pp. 293-300, 2014.
29. D. L. Catalfamo, N. L. Calderon, S. W. Harden, H. L. Sorenson, K. G. Neiva, and S. M. Wallet, "Augmented LPS responsiveness in type 1 diabetes-derived osteoclasts, " Journal of Cellular Physiology, vol. 228, no. 2, pp. 349-361, 2013.
30. J. A. F. Silva, D. Lopes-Ferrucci, L. A. Peroni et al., "Periodontal disease-associated compensatory expression of osteoprotegerin is lost in type 1 diabetes mellitus and correlates with alveolar bone destruction by regulating osteoclastogenesis, " Cells Tissues Organs, vol. 196, no. 2, pp. 137-150, 2012.
31. J. C.-H. Hou, R. F. Zernicke, and R. J. Barnard, "Effects of severe diabetes and insulin on the femoral neck of the immature rat, " Journal of Orthopaedic Research, vol. 11, no. 2, pp. 263-271, 1993.
32. S. Botolin, M.-C. Faugere, H. Malluche, M. Orth, R. Meyer, and L. R. McCabe, "Increased bone adiposity and peroxisomal proliferator-activated receptor-β2 expression in type I diabetic mice, " Endocrinology, vol. 146, no. 8, pp. 3622-3631, 2005.
33. K. J. Motyl, S. Botolin, R. Irwin et al., "Bone inflammation and altered gene expression with type Idiabetes early onset, " Journal of Cellular Physiology, vol. 218, no. 3, pp. 575-583, 2009.
34. S. J. Gallacher, J. A. K. Fenner, B. M. Fisher et al., "An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus, " Diabetic Medicine, vol. 10, no. 2, pp. 129-133, 1993.
35. A. B. R. Maggio, S. Ferrari, M. Kraenzlin et al., "Decreased bone turnover in children and adolescents with well controlled type diabetes, " Journal of Pediatric Endocrinology and Metabolism, vol. 23, no. 7, pp. 697-707, 2010.
36. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, "Advanced glycation end products: sparking the development of diabetic vascular injury, " Circulation, vol. 114, no. 6, pp. 597-605, 2006.
37. M. J. Silva, M. D. Brodt, M. A. Lynch et al., "Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life, " Journal of Bone and Mineral Research, vol. 24, no. 9, pp. 1618-1627, 2009.
38. T. Neumann, S. Lodes, B. Kastner et al., "High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control, " Osteoporosis International, vol. 25, no. 5, pp. 1527-1533, 2014.
39. M. Saito and K. Marumo, "Bone quality in diabetes, " Frontiers in Endocrinology, vol. 4, article 72, Article IDArticle 72, pp. 1-9, 2013.
40. V. M. Monnier, D. R. Sell, Z. Dai, I. Nemet, F. Collard, and J. Zhang "The role of the Amadori product in the complications of diabetes, " Annals of the New York Academy of Sciences, vol. 1126, pp. 81-88, 2008.
41. N. Mercer, H. Ahmed, S. B. Etcheverry, G. R. Vasta, and A. M. Cortizo, "Regulation of advanced glycation end product (AGE) receptors and apoptosis byAGEs in osteoblast-like cells, " Molecular and Cellular Biochemistry, vol. 306, no. 1-2, pp. 87-94, 2007.
42. L. A. Ahmed, R. M. Joakimsen, G. K. Berntsen, V. Fnneb, and H. Schirmer, "Diabetes mellitus and the risk of non-vertebral fractures: the Troms study, " Osteoporosis International, vol. 17, pp. 495-500, 2006.
43. G. Karaguzel, S. Akcurin, S. Ozdem, A. Boz, and I. Bircan, "Bone mineral density and alterations of bone metabolism in children and adolescents with type 1 diabetes mellitus, " Journal of Pediatric Endocrinology and Metabolism, vol. 19, no. 6, pp. 805-814, 2006.
44. C. Eller-Vainicher, V. V. Zhukouskaya, Y. V. Tolkachev et al., "Low bone mineral density and its predictors in type 1 diabetic patients evaluated by the classic statistics and artificial neural network analysis, " Diabetes Care, vol. 34, no. 10, pp. 2186-2191, 2011.
45. E. J. Hamilton, V. Rakic, W. A. Davis et al., "Afive-year prospective study of bone mineral density in men and women with diabetes: the FremantleDiabetes Study, " Acta Diabetologica, vol. 49, no. 2, pp. 153-158, 2012.
46. R. E. Maser, P. Kolm, C. M. Modlesky, T. J. Beck, and M. J. Lenhard, "Hip strength in adults with Type 1 diabetes is associated with age at onset of diabetes, " Journal of Clinical Densitometry, vol. 15, no. 1, pp. 78-85, 2012.
47. V. V. Zhukouskaya, C. Eller-Vainicher, V. V. Vadzianava et al. "Prevalence of morphometric vertebral fractures in patients with type 1 diabetes, " Diabetes Care, vol. 36, no. 6, pp. 1635-1640, 2013.
48. A. B. R. Maggio, R. R. Rizzoli, L. M. Marchand, S. Ferrari, M. Beghetti, and N. J. Farpour-Lambert, "Physical activity increases bone mineral density in children with type 1 diabetes, " Medicine and Science in Sports and Exercise, vol. 44, no. 7, pp. 1206-1211, 2012.
49. E. Y. Liu, J. Wactawski-Wende, R. P. Donahue, J. Dmochowski, K. M. Hovey, and T. Quattrin, "Does low bone mineral density start in post-teenage years in women with type 1 diabetes?" Diabetes Care, vol. 26, no. 8, pp. 2365-2369, 2003.
50. A. Joshi, P. Varthakavi, M. Chadha, and N. Bhagwat, "A study of bone mineral density and its determinants in type 1 diabetes mellitus, " Journal of Osteoporosis, vol. 2013, Article ID 397814, 8 pages, 2013.
51. G. Valerio, A. del Puente, A. Esposito-del Puente, P. Buono, E. Mozzillo, and A. Franzese, "The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus, " Hormone Research, vol. 58, no. 6, pp. 266-272, 2002.
52. I. Roggen, I. Gies, J. Vanbesien, O. Louis, and J. de Schepper, "Trabecular bone mineral density and bone geometry of the distal radius at completion of pubertal growth in childhood Type 1 diabetes, " Hormone Research in Paediatrics, vol. 79, no. 2, pp. 68-74, 2013.
53. E. J. Hamilton, V. Rakic, W. A. Davis et al., "Prevalence and predictors of osteopenia and osteoporosis in adults with Type diabetes, " Diabetic Medicine, vol. 26, no. 1, pp. 45-52, 2009.
54. K. K. Danielson, M. E. Elliott, T. Lecaire, N. Binkley, and M. Palta, "Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes, " Osteoporosis International, vol. 20, no. 6, pp. 923-933, 2009.
55. E. M. Lochmuller, D. Burklein, V. Kuhn et al., "Mechanical strength of the thoracolumbar spine in the elderly: Prediction from in situ dual-energy X-ray absorptiometry, quantitative computed tomography (QCT), upper and lower limb peripheral QCT, and quantitative ultrasound, " Bone, vol. 31, no. 1, pp. 77-84, 2002.
56. E. Seeman, "Bone quality, " in Essays in Bone Quality-Selected Review Articles From Advances in Osteoporotic Fracture Management, I. Lieberman and F. Phillips, Eds., pp. 1-8, Remedica Publishing, Chicago, Ill, USA, 2004.
57. L. J. Moyer-Mileur, S. B. Dixon, J. L. Quick, E. W. Askew, and M. A. Murray, "Bone mineral acquisition in adolescents with type 1 diabetes, " Journal of Pediatrics, vol. 145, no. 5, pp. 662-669, 2004.
58. M. T. Saha, H. Sievanen, M. K. Salo, S. Tulokas, and H. H. Saha, "Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers, " Osteoporosis International, vol. 20, no. 8, pp. 1401-1406, 2009.
59. S. Bechtold, S. Putzker, W. Bonfig, O. Fuchs, I. Dirlenbach, and H. P. Schwarz, "Bone size normalizes with age in children and adolescents with type 1 diabetes, " Diabetes Care, vol. 30, no. 8, pp. 2046-2050, 2007.
60. T. L. N. Jarvinen, H. Sievanen, J. Jokihaara, and T. A. Einhorn, "Revival of bone strength: the bottom line, " Journal of Bone and Mineral Research, vol. 20, no. 5, pp. 717-720, 2005.
61. N. Follack, I. Kloting, E. Wolf, and E. Merk, "Improving metabolic control reverses the histomorphometric and biomechanical abnormalities of an experimentally induced bone defect in spontaneously diabetic rats, " Calcified Tissue International, vol. 74, no. 6, pp. 551-560, 2004.
62. N. Erdal, S. Gurgul, C. Demirel, and A. Yildiz, "The effect of insulin therapy on biomechanical deterioration of bone in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats, " Diabetes Research and Clinical Practice, vol. 97, no. 3, pp. 461-467, 2012.
63. P. Vestergaard, L. Rejnmark, and L. Mosekilde, "Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk, " Diabetologia, vol. 48, no. 7, pp. 1292-1299, 2005.
64. A. Papaioannou, S. Morin, A. M. Cheung et al., "2010 clinical practice guidelines for the diagnosis andmanagement of osteoporosis in Canada: summary, " Canadian Medical Association Journal, vol. 182, no. 17, pp. 1864-1873, 2010.
65. NationalOsteoporosis Foundation, Clinicians'Guide for Prevention and Treatment of Osteoporosis, 2010, http://nof.org/files/nof/public/content/file/344/upload/159.pdf.
66. Canadian Diabetes Association, Clinical Practice Guidelines, Canadian Diabetes Association, Toronto, Canada, 2013, http://guidelines.diabetes.ca.
67. American Diabetes Association, "Standards of medical care in diabetes-2014, " Diabetes Care, vol. 37, supplement 1, pp. S14-S80, 2014.
68. L. Ryden, P. J. Grant, S. D. Anker et al., "ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary, " European Heart Journal, vol. 34, pp. 3035-3087, 2013, ErratuminEuropeanHeart Journal, vol. 35, no. 27, p. 1824, 2014.
69. National Institute of Health and Care Excellence (NICE), Type Diabetes: Diagnosis and Management of Type 1 Diabetes in Children Young People and Adults, 2004, http://www.nice.org .uk/guidance/CG15/chapter/1-Guidance#/#complications-andassociated-conditions
70. M. Bonyadi, S. D. Waldman, D. Liu, J. E. Aubin, M. D. Grynpas, and W. L. Stanford, "Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5840-5845, 2003.
71. C. Holmes, T. S. Khan, C. Owen, N. Ciliberti, M. D. Grynpas, and W. L. Stanford, "Longitudinal analysis of mesenchymal progenitors and bone quality in the stem cell antigen-1-null osteoporoticmouse, " Journal of Bone andMineral Research, vol. 22, no. 9, pp. 1373-1386, 2007.
72. W. C. Prall, F. Haasters, J. Heggebo et al., "Mesenchymal stem cells from osteoporotic patients feature impaired signal transduction but sustained osteoinduction in response to BMP stimulation, " Biochemical and Biophysical Research Communications, vol. 440, no. 4, pp. 617-622, 2013.
73. A. M. Pino, C. J. Rosen, and J. P. Rodr?guez, "In Osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis, " Biological Research, vol. 45, no. 3, pp. 279-287, 2012.
74. L. Tauchmanova, P. Ricci, B. Serio et al., "Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation, " The Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 2, pp. 627-634, 2005.
75. V. Ribeiro, M. Garcia, R. Oliveira, P. S. Gomes, B. Colaco, and M. H. Fernandes, "Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells, " Journal of Cellular and Molecular Medicine, vol. 18, no. 1, pp. 27-37, 2014.
76. R. Ebert, S. Zeck, R. Krug et al., "Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation, " Bone, vol. 44, no. 5, pp. 858-864, 2009.
77. D. M. Black, S. L. Greenspan, K. E. Ensrud et al., "The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, " The New England Journal of Medicine, vol. 349, no. 13, pp. 1207-1215, 2003.
78. T. H. M. Keegan, A. V. Schwartz, D. C. Bauer, D. E. Sellmeyer, and J. L. Kelsey, "Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial, " Diabetes Care, vol. 27, no. 7, pp. 1547-1553, 2004.
79. P. Vestergaard, L. Rejnmark, and L. Mosekilde, "Are antiresorptive drugs effective against fractures in patients with diabetes?" Calcified Tissue International, vol. 88, no. 3, pp. 209-214, 2011.
80. L. Y. Park-Wyllie, M. M. Mamdani, D. N. Juurlink et al., "Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women, " The Journal of the American Medical Association, vol. 305, no. 8, pp. 783-789, 2011.
81. K. J. Motyl, L. K. McCauley, and L. R. McCabe, "Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival, " Journal of Cellular Physiology, vol. 227, no. 4, pp. 1326-1334, 2012.
82. M. R. McClung, A. Grauer, S. Boonen et al., "Romosozumab in postmenopausal women with low bone mineral density, " The New England Journal of Medicine, vol. 370, no. 5, pp. 412-420, 2014.
83. C. Hamann, M. Rauner, Y. Hohna et al., "Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus, " Journal of Bone and Mineral Research, vol. 28, no. 3, pp. 627-638, 2013.
84. J.-Y. Kim, S.-K. Lee, K.-J. Jo et al., "Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes, " Life Sciences, vol. 92, no. 10, pp. 533-540, 2013.